{"id":50309,"date":"2022-11-01T09:02:08","date_gmt":"2022-11-01T08:02:08","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/"},"modified":"2022-11-01T09:02:08","modified_gmt":"2022-11-01T08:02:08","slug":"memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/","title":{"rendered":"Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets"},"content":{"rendered":"
\n

SCHLIEREN, Switzerland & OSAKA, Japan–(BUSINESS WIRE)–Memo Therapeutics AG<\/a> (\u201cMTx\u201d), an innovator in the field of antibody discovery and development, announced today the signing of a research and development collaboration agreement with Ono Pharmaceutical Co. Ltd (\u201cOno\u201d). Under the terms of the agreement, MTx will leverage its best-in-class microfluidic single-cell molecular cloning and screening technologies to discover antibodies for immuno-oncology targets.\n<\/p>\n

<\/a><\/p>\n

\nOno will acquire intellectual property rights and worldwide exclusive rights to develop and commercialize therapeutic drug candidates with antibodies resulting from the collaboration. MTx will receive an upfront payment, research funding during the collaboration period, clinical development and sales milestones, as well as royalties on future sales.\n<\/p>\n

\n\u201cOno with their proven track-record in the immune-oncology space is an ideal partner to advance this program. We are delighted to take this important step as the partnership recognizes our platform\u2019s ability to identify high-value targets and create functionally superior antibodies in the immuno-oncology field,\u201d said Dr. Christoph Esslinger, Chief Scientific Officer and founder of Memo Therapeutics AG.\n<\/p>\n

\n\u201cWe look forward to collaborating with Memo Therapeutics AG\u2019s team of antibody scientists through this collaboration and hope that the candidates generated through our collaboration will add to our current portfolio of medicines to help cancer patients in immuno-oncology,\u201d said Toichi Takino, Senior Executive Officer \/ Executive Director, Discovery & Research of Ono Pharmaceutical.\n<\/p>\n

\nAbout Memo Therapeutics AG<\/a><\/b>\n<\/p>\n

\nMemo Therapeutics AG is an innovator in the field of antibody discovery and immune repertoire analysis. The company\u2019s antibody discovery platform uses robust, simple, and fast microfluidic single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery at unprecedented speed, efficiency, and sensitivity.\n<\/p>\n

\nExploiting the power of its microfluidic single-cell molecular cloning and screening technologies, Memo Therapeutics AG engages in antibody discovery across species and indications for proprietary and partnered projects. The company\u2019s current pipeline features programs in infectious diseases and immuno-oncology. Memo Therapeutics AG is a private company located in Bio-Technopark Schlieren\/Zurich, Switzerland.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nMemo Therapeutics AG
\n
Karsten Fischer
\n
media@memo-therapeutics.com<\/a><\/p>\n

Halsin Partners
\n
Mike Sinclair
\n
+44 (0) 7968 022075
\n
msinclair@halsin.com<\/a>\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

SCHLIEREN, Switzerland & OSAKA, Japan–(BUSINESS WIRE)–Memo Therapeutics AG (\u201cMTx\u201d), an innovator in the field of antibody discovery and development, announced today the signing of a research and development collaboration agreement with Ono Pharmaceutical Co. Ltd (\u201cOno\u201d). Under the terms of the agreement, MTx will leverage its best-in-class microfluidic single-cell molecular cloning and screening technologies to … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50309","6":"format-standard","7":"category-industry"},"yoast_head":"\nMemo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"SCHLIEREN, Switzerland & OSAKA, Japan–(BUSINESS WIRE)–Memo Therapeutics AG (\u201cMTx\u201d), an innovator in the field of antibody discovery and development, announced today the signing of a research and development collaboration agreement with Ono Pharmaceutical Co. Ltd (\u201cOno\u201d). Under the terms of the agreement, MTx will leverage its best-in-class microfluidic single-cell molecular cloning and screening technologies to ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-01T08:02:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221101005105\/en\/1618673\/21\/memoAG_logo_green_dark.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets\",\"datePublished\":\"2022-11-01T08:02:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\\\/\"},\"wordCount\":356,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221101005105\\\/en\\\/1618673\\\/21\\\/memoAG_logo_green_dark.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\\\/\",\"name\":\"Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221101005105\\\/en\\\/1618673\\\/21\\\/memoAG_logo_green_dark.jpg\",\"datePublished\":\"2022-11-01T08:02:08+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221101005105\\\/en\\\/1618673\\\/21\\\/memoAG_logo_green_dark.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221101005105\\\/en\\\/1618673\\\/21\\\/memoAG_logo_green_dark.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/","og_locale":"en_US","og_type":"article","og_title":"Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets - Pharma Trend","og_description":"SCHLIEREN, Switzerland & OSAKA, Japan–(BUSINESS WIRE)–Memo Therapeutics AG (\u201cMTx\u201d), an innovator in the field of antibody discovery and development, announced today the signing of a research and development collaboration agreement with Ono Pharmaceutical Co. Ltd (\u201cOno\u201d). Under the terms of the agreement, MTx will leverage its best-in-class microfluidic single-cell molecular cloning and screening technologies to ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-01T08:02:08+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221101005105\/en\/1618673\/21\/memoAG_logo_green_dark.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets","datePublished":"2022-11-01T08:02:08+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/"},"wordCount":356,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221101005105\/en\/1618673\/21\/memoAG_logo_green_dark.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/","url":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/","name":"Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221101005105\/en\/1618673\/21\/memoAG_logo_green_dark.jpg","datePublished":"2022-11-01T08:02:08+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221101005105\/en\/1618673\/21\/memoAG_logo_green_dark.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221101005105\/en\/1618673\/21\/memoAG_logo_green_dark.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/memo-therapeutics-ag-and-ono-pharmaceutical-enter-antibody-discovery-partnership-for-immuno-oncology-targets\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Memo Therapeutics AG and Ono Pharmaceutical Enter Antibody Discovery Partnership for Immuno-oncology Targets"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50309"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50309\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50309"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50309"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}